Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Trading Statement

25 Jun 2014 07:00

RNS Number : 4709K
Synectics PLC
25 June 2014
 

 

For immediate release

25 June 2014

 

 

Synectics plc

("the Company" or "the Group")

 

Trading Statement

 

Synectics plc (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, provides the following update on trading.

 

Synectics has suffered recent negative impacts that have substantially lowered its expectations of results, both for the first half year to 31 May 2014, and for the year to 30 November 2014, which are expected to be significantly below market expectations. However, trading for the second half of this year is expected to be very strong and well ahead of the record results achieved in the second half of last year (underlying PBT of £3.5 million). This is supported by substantial growth in the Group's consolidated order book, which stood at £32.9 million at 31 May 2014 (30 November 2013: £27.6 million), and particularly by an increase of 34% in the Group's qualified pipeline of anticipated orders to £46.8 million at 31 May 2014 (30 November 2013: £35.0 million). The Company's expectations for the 2015 financial year remain unchanged.

 

The Company indicated in its last annual report that results in the first half of this year would be significantly below those in 2012/13. Due to the impact of the issues referred to below, results for the half year ended 31 May 2014 are now expected to show an underlying loss before tax of approximately £2.5 million. The Company does not expect to report any non-underlying restructuring costs for either the half year or full year in 2013/14. As a result of the loss expected to be reported for the first half, the Board does not propose to pay an interim dividend. However, on the basis that trading is as strong as anticipated in the second half, the Board's intention would be to recommend payment of a final dividend at the same level as that of last year.

 

The largest impact on the full year results to 30 November 2014 is due to the current events in Iraq. Specifically, due to delays in awarding three oil & gas surveillance systems contracts for re-building and expanding oil refineries in southern Iraq, a total of around £7 million of revenue and just over £2.1 million of net profit contribution to the Group have been removed from the business' forecasts for the second half of this financial year. It is impossible to say at this stage when or whether these delays will be resolved, and the Company's expectations for the 2015 financial year are not dependent on any such resolution.

 

There are two issues that have had a negative impact on the Group's half year results to 31 May 2014. The first of these relates to the UK systems integration activities within Synectics' Integration & Managed Services division where local management have been implementing a new management information system, as well as significant changes in organisation structure and management personnel. It is now apparent that during this process, a large surveillance system integration project suffered much more seriously than was at first believed due mainly to a combination of external difficulties beyond Synectics' control as well as inadequate internal project management. These problems led to delays, inefficiencies and an unexpectedly large cost overrun. A full review of all projects by the newly-appointed divisional Finance Director has revealed a need for substantially increased provisions for additional costs and reduced forecast future revenues on this project. There are no other material loss-making projects. The total negative impact of the reduced revenues and additional costs incurred or provided for on this project, compared with the original bid margin, is around £1.9 million, of which the larger part is in the first half to 31 May 2014.

 

Group management has already taken decisive action to address the issues at the root of the problem and the Board believes that the project is now back under control. Underlying trading for the integration business and the division as a whole is now positive, and results for the second half of this year are expected to be at levels consistent with recent years. Market conditions in the sector remain generally favourable.

 

Secondly, as reported in the Company's last annual report, the rapid growth of Synectics' Systems division over the past several years created an imperative to move and consolidate two of the division's operations facilities into a single new site, with expanded capacity. To that end, the Group has purchased and refurbished a 54,000 square foot freehold building in Scunthorpe, and the move of plant and personnel from both operations into this new facility has just been successfully completed. The benefits of much increased capacity for both production and customer acceptance tests, as well as improved efficiencies, are already very evident. Nevertheless, the impact of disruption to operations during the transition in the first half of this year has been beyond that originally envisaged.

 

Synectics' global high-end surveillance markets remain robust, particularly in the oil & gas and gaming sectors. On the basis of the current growth being seen in the Group's pipeline of new business, and the recent major investments in new facilities and infrastructure, the Company expects that the strong level of anticipated trading in the second half of the current year will continue in the 2015 financial year.

 

Results for the half year to 31 May 2014 will be released on 29 July 2014.

 

For further information, please contact:

Synectics plc

Tel: +44 (0) 1527 850 080

John Shepherd, Chief Executive

www.synecticsplc.com

email: info@synecticsplc.com

Westhouse Securities Limited

Tel: +44 (0) 207 601 6100

Tom Griffiths

Media enquiries:

Buchanan

Tel: +44 (0) 207 466 5000

Mark Court / Fiona Henson / Sophie Cowles

email: Synectics@buchanan.uk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFAMATMBTTMPI
Date   Source Headline
30th Mar 20114:35 pmRNSAvailability of Report & Accounts
8th Mar 20117:00 amRNSRe: 2009 Group Executive Shared Ownership Plan
4th Mar 20117:00 amRNSPreliminary Results
1st Feb 201111:06 amRNSNotification of Results
7th Jan 20114:02 pmRNSHolding(s) in Company
4th Jan 20117:00 amRNSAcquisition
21st Dec 201010:45 amRNSHolding(s) in Company
21st Dec 20107:00 amRNSHolding(s) in Company
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20107:00 amRNSPost Year End Trading Update
27th Jul 20107:00 amRNSInterim Results
3rd Feb 20107:00 amRNSInterim Results
21st Jan 201010:36 amRNSContract Win
15th Jan 20102:59 pmRNSREPLACEMENT: Notice of Results
15th Jan 201010:35 amRNSNotice of Results
11th Nov 200910:59 amRNSResult of AGM
5th Nov 20097:00 amRNSTrading Update
9th Sep 20097:00 amRNSPreliminary Results
16th Jun 20097:00 amRNSStructural and Strategic Reorganisation
4th Feb 20097:00 amRNSInterim Results
16th Jan 200912:06 pmRNSNotification of Results
3rd Sep 20087:00 amRNSPreliminary Results
6th Feb 20087:01 amRNSInterim Results
16th Jan 20087:00 amRNSNotification of Results
6th Dec 20071:09 pmRNSCanc of AIM trading facility
6th Dec 20079:56 amRNSOffer Update
30th Nov 20077:01 amRNSOffer Update
29th Nov 20077:01 amRNSOffer Update
26th Nov 200712:34 pmRNSResult of EGM
23rd Nov 20079:57 amRNSRule 8.1- Synexus
19th Nov 20079:40 amRNSRule 8.1- Synexus
16th Nov 200710:00 amRNSRule 8.1- Synexus
15th Nov 20073:00 pmBUSRule 8.3 - Synexus Clinincal Research Plc
15th Nov 200712:07 pmBUSRule 8.3 - Synexus Clinical Research Plc
15th Nov 20079:16 amRNSRule 8.1- Synexus
14th Nov 20073:21 pmBUSRule 8.3 - Synexus Clinical Research Plc
13th Nov 20073:16 pmBUSRule 8.3 - Synexus Clinical Research Plc
7th Nov 20074:38 pmRNSOffer Document Posted
7th Nov 20077:02 amRNSOffer for Synexus
6th Nov 20079:10 amRNSRule 8.3- Synexus
22nd Oct 200710:46 amRNSHolding(s) in Company
19th Oct 20076:21 pmRNSResponse to price movement
28th Sep 20077:02 amRNSPre Close Statement
5th Sep 20078:33 amRNSBoard Change
5th Sep 20077:01 amRNSPreliminary Results
22nd Aug 20073:17 pmRNSHolding(s) in Company
22nd Aug 200711:19 amRNSAIM RULE 26
15th Jun 20071:26 pmRNSGrant of Options
13th Jun 20077:01 amRNSPreliminary Results
24th May 20074:24 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.